reduced intensity allogeneic HCT

PreclinicalBiologic

MMasonic Cancer Center, University of Minnesota

reduced intensity allogeneic HCT is one of 6 biologic programs targeting Hematopoietic Stem Cell Transplant. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematopoietic Stem Cell TransplantTerminated

Hematopoietic Stem Cell TransplantPreclinical

Terminated

Competition

Competitive Landscape

7 competitors in Hematopoietic Stem Cell Transplant

#DrugCompanyPhaseTrials

Jakafi

Incyte

Phase 2

2 2

Clolar

GGenzyme, a Sanofi Company

Preclinical

1 3

Cyclosporine a

Novartis

Preclinical

1 4

Campath 1h

Mario Negri Institute for Pharmacological Research

Preclinical

1 5

reduced intensity allogeneic HCT

MMasonic Cancer Center, University of Minnesota

Preclinical

1 6

Myeloablative Busulfan

MMasonic Cancer Center, University of Minnesota

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hematopoietic Stem Cell Transplant1 trial

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT02179359·38 enrolled

Hematopoietic Cell Transplant1 trial

Preservation of Ovarian Function After Hematopoietic Cell Transplant

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01343368·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for reduced intensity allogeneic HCT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — reduced intensity allogeneic HCT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for reduced intensity allogeneic HCT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMasonic Cancer Center, University of Minnesota

reduced intensity allogeneic HCT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hematopoietic Stem Cell Transplant1 trial

Hematopoietic Cell Transplant1 trial

References

Drug Info

Quick Facts

Related News